Coronavirus: Hungary grants initial approval for AstraZeneca, Sputnik V vaccines

Published: Updated:
Read Mode
100% Font Size
4 min read

Hungary’s drug regulator has given initial approval for use of Britain’s AstraZeneca and Russia’s Sputnik V vaccines against the coronavirus, Prime Minister Viktor Orban’s chief of staff said on Thursday, confirming media reports.

Foreign Minister Peter Szijjarto was travelling to Moscow for talks about the Sputnik V vaccine later on Thursday, Gergely Gulyas told a briefing.

Read the latest updates in our dedicated coronavirus section.

If he secures a shipment deal with Russia, Hungary would be the first European Union member to receive the Sputnik V shot, underlining Budapest’s rush to lift coronavirus lockdown measures in order to boost the economy, even though the EU’s medicines regulator has yet to green-light the Russian vaccine.

The European Medicines Agency (EMA) has also not approved the vaccine developed by AstraZeneca and Oxford University in Britain but a decision is expected on January 29.

 AstraZeneca's logo is reflected in a drop on a syringe needle in this illustration taken November 9, 2020. (Reuters)
AstraZeneca's logo is reflected in a drop on a syringe needle in this illustration taken November 9, 2020. (Reuters)

Gulyas said the Hungarian government would review current lockdown restrictions next week, but that the curbs were unlikely to be lifted until mass inoculations are carried out and the infection rate drops.

Gulyas said Russia’s supply problems with its vaccine seem to have been resolved and he hoped a “larger quantity” of the Sputnik V shot could be delivered to Hungary soon.

Kirill Dmitriev, CEO of the Russian Direct Investment Fund, said on Thursday Hungary has become the first country in the EU to “realize all the advantages of the Sputnik V vaccine and authorize its use.

“This decision is very important as it demonstrates that the vaccine’s safety and efficacy of over 90 percent are highly regarded by our partners in Hungary,” he said.

Scientists have raised concern about the speed at which Moscow has launched its vaccine, giving the regulatory go-ahead for the shot at home and launching mass vaccinations before full trials to test its safety and efficacy had been completed.

Moscow has said Sputnik V is 92 percent effective at protecting people from COVID-19 based on interim results but has not yet released the full dataset for the trials.

Russia on Wednesday filed for registration of the Sputnik V vaccine in the EU ahead of an EMA review next month.

Read more:

UAE approves Russia’s Sputnik COVID-19 vaccine for emergency use

Russia files Sputnik V COVID-19 vaccine registration in Europe

Sputnik-AstraZeneca vaccine trials to start in February, says R-Pharm

Top Content Trending